Remedium has teamed up with a UK company to maximize the production of technical-grade lithium carbonate in order to satisfy the growing demand for electric vehicles.
Remedium Lifecare Ltd., formerly known as Roxy Exports, declared on Monday that it had signed a major contract with Angel Partners, Ltd. to purchase the technology needed to produce lithium carbonate in India. By taking this calculated risk, Remedium hopes to establish itself as a major player in the lithium-ion battery industry and satisfy the expanding market for portable gadgets and electric cars.
Additionally, on that same day, Remedium Lifecare inked an annual supply agreement with Alfa Chemicals and Solvents, Turkey. This arrangement guarantees a consistent supply of technical-grade lithium carbonate and is scheduled to start in the January–March 2025 quarter. The supplies for 2025, estimated to be worth USD 20–25 million, highlight the significant scope of this collaboration. This calculated decision is a critical milestone in our development and expansion as it will greatly increase our manufacturing capacity and enable us to satisfy the growing market demand.
The supply value of $1.67–2.1 billion for 2025 is outlined in the agreement with Alfa Chemicals and Solvents Ltd., underscoring the possible effects of this relationship on Remedium’s operations. This large investment highlights the role that lithium carbonate plays in the developing market for battery technology. Remedium Lifecare Ltd. enhances its market position and advances the wider adoption of electric vehicles and sustainable energy solutions by obtaining these partnerships.
